A victory by Mylan in the court case could lead it to start a generic as soon as the Food and Drug Administration approves its pending application, Gal said."Barring large industry fluctuations, we anticipate much of the same until the company closes its proposed merger with Pfizer’s generic arm in the second half of the fiscal year.” Biogen shares recently traded at $267.28, down 5.04%.